A15-year-old girl was referred to a pediatric endocrinologist for evaluation of hyperthyroidism. Her primary concerns were intermittent increases in heart rate and appetite (with a weight gain of 7 kg within the past year), feeling hot at night even in winter, persistent lower extremity edema that had been present since age 4 years, and difficulty in concentrating. She denied having diarrhea, sweating, fatigue, breathing difficulties, hair loss, or changes in hair texture.
For 3 days, a 7-year-old girl had severe, generalized abdominal pain. The patient described the pain as sharp and achy without radiation; she denied any relieving or aggravating factors. She also reported decreased appetite and energy for the past week.
The rash on this 4-week-old girl had appeared 5 days earlier on her face as thickened scales on an erythematous base and subsequently spread to the scalp, shoulder, chest, abdomen, and extremities. A few bullae were noted on the neck and hands. Initial treatment with cephalexin failed to control the rash, and the infant was admitted to the hospital for further evaluation.
Androgen deprivation therapy (ADT) has been used in the management of prostate cancer for more than four decades. Initially, hormone therapy was given largely for palliation of symptomatic metastases. Following several randomized trials of patients with intermediate- to high-risk prostate cancer that demonstrated improvements in biochemical control and survival with the addition of ADT to external beam radiotherapy, there was a dramatic increase in the use of hormone therapy in the definitive... More »
The role, timing, and clinical use of androgen deprivation therapy (ADT) in prostate cancer remain a controversial topic for clinicians. Drs. Fang, Merrick, and Wallner provide a compelling review of the clinical benefits and side effects of ADT in high-risk prostate cancer. The number of patients presenting with advanced disease remains significant despite the stage migration of prostate cancer during the PSA (prostate-specific antigen) era. More »
Androgen deprivation therapy (ADT) has been shown to be beneficial in combination with radiotherapy (RT) vs RT alone in multiple phase III randomized trials treating patients with high-risk prostate cancer. Drs. Fang, Merrick, and Wallner have concisely summarized the data in Table 1 of their article. The Radiation Therapy Oncology Group trial RTOG 86-10 has demonstrated that as little as 4 months of ADT in combination with RT can delay the time to development of metastatic disease by up to 8... More »
Prostate cancer is the second most common cause of cancer death in American men. What to do when prostate cancer recurs months or years after a patient undergoes radical prostatectomy is an area of active research. Patients who underwent radical prostatectomy without immediate adjuvant radiation therapy (ART) but subsequently have evidence of recurrent disease are candidates for Salvage Radiation Therapy (SRT). Though there are three prospective randomized trials illustrating the efficacy of... More »
Despite the common use of postoperative radiotherapy (RT) in patients managed initially with radical prostatectomy (RP), a number of questions remain. Raldow and colleagues build their arguments around three randomized trials that indicated a significant benefit of immediate adjuvant radiotherapy in patients with high-risk features. More »
No in that we will continue to publish articles across the entire spectrum of prostatecancer from population base ...ProstateCancer and Prostatic Diseases and the betterment of science as a whole. I will strive to make this journal ...
The objective of this study was to determine whether screening for prostatecancer (PC) reduces PC mortality and if so whether ... Personal subscribers to ProstateCancer and Prostatic Diseases can view this article. To do this associate your subscription with your registration via the ...
Cancer Mortality in Men With Early-Stage ProstateCancer" Richard J. Ablin PhD; Oliver Sartor MD; ... increase in a lifetime risk of a diagnosis of prostatecancer owing to PSA screening prostatecancer represents one of the most ...
doi:10.1038/pcan.2010.14; published online 3 August 2010 The implementation of screening for prostatecancer... The objective of this study was to determine whether screening for prostatecancer (PC) reduces PC mortality and if so whether ...
4.8-month improvement in overall survival in advanced prostatecancer patients and was well tolerated. ...cancer should not be dismissed. Results with another vaccine in prostatecancer are similar perhaps suggesting a class effect. ...
Effect of dutasteride on the risk of prostatecancer. N Engl J Med 2010;362:1192–202. ...cancer. First and foremost canceroftheprostate is almost an inevitable consequence of getting older. ...
prostate-specific antigen (PSA) do not have prostatecancer leading to a large number of unnecessary biopsies. ... elevated PSA (X3 ng ml ) with 110 prostatecancers detected (12%). ...
Urologic Oncology Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant ProstateCancer... an antisense inhibitor of clusterin in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostatecancer. ...
Men considering the prostate specific antigen (PSA) test for prostatecancer an increasingly common male cancer are encouraged to make informed ... informed decision making: (1) knowledge of prostatecancer and PSA (2) attitude toward PSA testing ...
cancer management and prognosis. We also wanted to quantify the impact of pre-existing diabetes on prostatecancer-specific and overall mortality. ... 90 excluded from prostatecancer paper - 12 repeated analyses in a single population - 78 did not assess prostatecancer outcomes ...
are associated with focal therapy for men with localized prostatecancer. MATERIAL AND METHODS: Urologic surgeons radiation oncologists radiologists ... Europe participated in a consensus workshop on focal therapy for prostatecancer. The consensus process was face to face within a structured ...
Hormone therapy is the treatment of choice for patients with metastaticprostatecancer. The preferred methods are bilateral orchiectomy luteinising hormone ... Intermittent hormone therapy for patients with metastaticprostatecancer is an experimental approach that is preferably given in the context ...
AIM: To define the role of rehabilitation in the prostatecancer patient who has undergone radical prostatectomy (RP). ... recommendations were arrived at for clinicians treating men with prostatecancer before and after definitive surgical management. ...